30 or 60 mg ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 67 | Polycystic kidney disease | 1 |
67. Polycystic kidney disease
Clinical trials : 221 / Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-004115-39-DK (EUCTR) | 08/02/2018 | 13/12/2017 | Same as above | Subacute Effect of Tolvaptan on Total Kidney Volumen in Adult Patients with Autosomal Dominant Polycystic Kidney Disease | Autosomal Dominant Polycystic Kidney DIsease MedDRA version: 20.0;Level: LLT;Classification code 10036045;Term: Polycystic kidney;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Jinarc 15 mg tablets, Jinarc 45 mg tablets Product Name: Jinarc - Tolvaptan tablets Product Code: 15 or 45 mg INN or Proposed INN: Tolvaptan Other descriptive name: TOLVAPTAN Trade Name: Jinarc 30 mg tablets, Jinarc 60 mg tablets Product Name: Jinarc - Tolvaptan tablets Product Code: 30 or 60 mg INN or Proposed INN: Tolvaptan Other descriptive name: TOLVAPTAN Trade Name: Jinarc 30 mg tablets, 90 mg tablets Product Name: Jinarc - Tolvaptan tablets Product Code: 30 or 90 mg INN or Proposed INN: Tolvaptan Other descriptive name: TOLVAPTAN | Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 90 | Phase 4 | Denmark |